Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Scott

Showing results (51-60 of 147) with videos related to

Pageof 15
Sort By:
Therapeutic Advances in Cardiovascular Disease|July 6, 2017
Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican HispanicsDagmar F Hernandez-Suarez, Stuart A Scott, Matthew I Tomey, et al.
Clinical Chemistry|January 3, 2025
Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)Li Gong, Clarissa J Klein, Kelly E Caudle, et al.
The Journal of Molecular Diagnostics : JMD|February 24, 2018
Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular PathologyVictoria M Pratt, Andria L Del Tredici, Houda Hachad, et al.
Genome Research|January 19, 2023
An efficient genotyper and star-allele caller for pharmacogenomicsAnanth Hari, Qinghui Zhou, Nina Gonzaludo, et al.
Genome Research|April 11, 2025
Analytical validation of germline small variant detection using long-read HiFi genome sequencingNathan Hammond, Linda Liao, Pun Wai Tong, et al.
Pharmacogenetics and Genomics|October 27, 2011
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19Stuart A Scott, Katrin Sangkuhl, Alan R Shuldiner, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
Current Opinion in Biotechnology|April 20, 2010
Biodiesel from algae: challenges and prospectsStuart A Scott, Matthew P Davey, John S Dennis, et al.
Clinical Pharmacology and Therapeutics|June 28, 2020
Clinical Pharmacogenetic Testing and the Posttest Counseling ConundrumRobert Rigobello, Shahad Rahawi, Richard Wallsten, et al.
American Journal of Medical Genetics. Part A|March 21, 2017
Maternal uniparental disomy of chromosome 15 and concomitant STRC and CATSPER2 deletion-mediated deafness-infertility syndromeLisa Karger, Wahab A Khan, Rafaela Calabio, et al.
Pageof 15

Showing results (51-60 of 147) with videos related to

Sort By:
Pageof 15
Therapeutic Advances in Cardiovascular Disease|July 6, 2017
Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican HispanicsDagmar F Hernandez-Suarez, Stuart A Scott, Matthew I Tomey, et al.
Clinical Chemistry|January 3, 2025
Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)Li Gong, Clarissa J Klein, Kelly E Caudle, et al.
The Journal of Molecular Diagnostics : JMD|February 24, 2018
Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular PathologyVictoria M Pratt, Andria L Del Tredici, Houda Hachad, et al.
Genome Research|January 19, 2023
An efficient genotyper and star-allele caller for pharmacogenomicsAnanth Hari, Qinghui Zhou, Nina Gonzaludo, et al.
Genome Research|April 11, 2025
Analytical validation of germline small variant detection using long-read HiFi genome sequencingNathan Hammond, Linda Liao, Pun Wai Tong, et al.
Pharmacogenetics and Genomics|October 27, 2011
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19Stuart A Scott, Katrin Sangkuhl, Alan R Shuldiner, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
Current Opinion in Biotechnology|April 20, 2010
Biodiesel from algae: challenges and prospectsStuart A Scott, Matthew P Davey, John S Dennis, et al.
Clinical Pharmacology and Therapeutics|June 28, 2020
Clinical Pharmacogenetic Testing and the Posttest Counseling ConundrumRobert Rigobello, Shahad Rahawi, Richard Wallsten, et al.
American Journal of Medical Genetics. Part A|March 21, 2017
Maternal uniparental disomy of chromosome 15 and concomitant STRC and CATSPER2 deletion-mediated deafness-infertility syndromeLisa Karger, Wahab A Khan, Rafaela Calabio, et al.
Pageof 15